Most investors have never heard of Clarivate. The company operates largely outside mainstream investor attention.
While the market fixates on AI darlings trading at triple-digit multiples, this London-based data intelligence company sits at $2.64 per share with a $1.67 billion market cap, quietly generating hundreds of millions in free cash flow and embedding itself deeper into the workflows of researchers, patent attorneys, and pharmaceutical scientists who cannot do their jobs without it.
Clarivate (NYSE:CLVT) owns some of the most defensible data assets in the world. Web of Science. Derwent. Cortellis. These aren’t household names, but inside a university library, a patent law firm, or a biopharma R&D team, they’re the only gas station for miles.
The Cash Flow Story Nobody Is Telling
Here’s what gets lost in the GAAP noise: Clarivate generated $628.5 million in operating cash flow in 2025 against a net loss of $201.1 million. That gap exists almost entirely because of $757.2 million in depreciation and amortization from years of acquisitions. The business bleeds cash in, not out.
Free cash flow came in at $365.3 million for the full year, and management is guiding for $365 million to $435 million in 2026. At the current market cap, you’re paying a modest multiple on real, tangible cash generation.
The Strategic Pivot That Changes Everything
Clarivate is actively selling its Life Sciences and Healthcare segment with Morgan Stanley advising. CEO Matti Shem Tov was direct on the earnings call:
“We believe selling this segment will allow further emphasis on the A&G and IP market and strengthen our balance sheet through reduced leverage. We are currently engaged in active discussions with interested parties.”
Against a $4.47 billion debt load, any meaningful sale proceeds could dramatically change the leverage picture. CFO Jonathan Collins was equally pointed: “Our judgment is that just based on the overall market environment, we will best serve all of our investors by focusing on deleveraging this year.”
AI as Amplifier, Not Threat
The bear case on data companies is that AI commoditizes their content. Clarivate’s answer is Cortellis: 3 million expertly curated safety and toxicity alerts continuously updated by in-house scientists. General-purpose AI can’t replicate that. The company also integrated its regulatory intelligence platform with Anthropic’s Claude via MCP, turning AI adoption into a distribution channel rather than a displacement risk.
“For us, AI is not a disruption to our business model; it is an amplifier of what already sets us apart,” Shem Tov said. With 97% of revenue from proprietary solutions and 88% recurring revenue mix, that’s a moat.
The debt is real, the GAAP losses are real, and the stock is down 39% over the past year. The outcome of the LS&H sale, the pace of deleveraging, and whether AI tailwinds accelerate the IP and academia businesses will be key factors shaping the company’s financial profile going forward.
Top Gaining Stocks
Top Losing Stocks